Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Company Data

Name Amylyx Pharmaceuticals, Inc. - Common Stock

Company Amylyx Pharmaceuticals, Inc.

Symbol AMLX

Website https://amylyx.com

Primary Exchange

NASDAQ

ISIN US03237H1014

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Joshua B. Cohen

Market Capitalization 718 Mio

Country United States of America

Currency USD

Employees 0,1 T

Address 43 Thorndike Street, 02141 Cambridge

IPO Date 2022-01-07

Dividends from 'Amylyx Pharmaceuticals, Inc. - Common Stock'

Ex-Date	Dividend per Share
28.03.2018	0,42 USD
28.12.2017	0,36 USD
28.09.2017	0,24 USD

Ticker Symbols

Name	Symbol
NASDAQ	AMLX

More Shares

Investors who hold Amylyx Pharmaceuticals, Inc. - Common Stock also have the following shares in their portfolio:

BRANDPILOT AI INC. Share

WRTS LKD ORDS WUHAN DEPT 11/03/25 Verbriefte Derivate

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog